Shin Nippon Biomedical Laboratories, Ltd. insider trades: Satsuma Pharmaceuticals (STSA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Shin Nippon Biomedical Laboratories, Ltd. reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 8, 2023 | STSA | ↑ Buy | 30,477,313 | $0.91 | $27.7M | Indirect | Jun 8, 2023 (0d) |
| Nov 16, 2015 | WVE | ↑ Buy | 125,000 | $16.00 | $2.0M | Indirect | Nov 18, 2015 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Shin Nippon Biomedical Laboratories, Ltd.'s insider trades
Shin Nippon Biomedical Laboratories, Ltd. is a 10% owner of Satsuma Pharmaceuticals (STSA). Since Nov 16, 2015, it has reported 2 open-market purchases worth $29.7M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include conversions (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every STSA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.